Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kezar Life Sciences (KZR) Research & Development (2021 - 2025)

Kezar Life Sciences' Research & Development history spans 5 years, with the latest figure at $6.9 million for Q3 2025.

  • For Q3 2025, Research & Development fell 57.43% year-over-year to $6.9 million; the TTM value through Sep 2025 reached $44.7 million, down 38.21%, while the annual FY2024 figure was $65.7 million, 23.29% down from the prior year.
  • Research & Development for Q3 2025 was $6.9 million at Kezar Life Sciences, down from $9.6 million in the prior quarter.
  • Across five years, Research & Development topped out at $23.7 million in Q3 2023 and bottomed at $6.9 million in Q3 2025.
  • The 5-year median for Research & Development is $13.9 million (2022), against an average of $14.2 million.
  • The largest annual shift saw Research & Development skyrocketed 85.08% in 2023 before it crashed 57.43% in 2025.
  • A 5-year view of Research & Development shows it stood at $9.8 million in 2021, then soared by 51.92% to $14.9 million in 2022, then soared by 52.38% to $22.6 million in 2023, then fell by 29.2% to $16.0 million in 2024, then tumbled by 56.87% to $6.9 million in 2025.
  • Per Business Quant, the three most recent readings for KZR's Research & Development are $6.9 million (Q3 2025), $9.6 million (Q2 2025), and $12.2 million (Q1 2025).